Comment on CMS-2026-1256-0002
Bristol Myers SquibbSupportAdvocacy
Summary: Bristol Myers Squibb supports the proposed methodology for MS-DRG 018 relative weight calculations, arguing it accurately reflects the resources required for CAR T cell therapies. The company also urges CMS to approve COBENFY for the New Technology Add-on Payment, arguing it meets all regulatory criteria for newness, cost, and substantial clinical improvement.
Bristol Myers Squibb appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services Fiscal Year 2027 Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospital Proposed Rule. Our comments are attached below.